Article thumbnail

Cilostazol Activates Function of Bone Marrow-Derived Endothelial Progenitor Cell for Re-endothelialization in a Carotid Balloon Injury Model

By Rie Kawabe-Yako, Ii Masaaki, Osamu Masuo, Takayuki Asahara and Toru Itakura
Topics: Research Article
Publisher: Public Library of Science
OAI identifier: oai:pubmedcentral.nih.gov:3171459
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2006). [Sirolimus inhibits the differentiation, proliferation and migration of endothelial progenitor cells in vitro].
  2. (2006). Activation of endothelial nitric oxide synthase by cilostazol via a cAMP/protein kinase A- and phosphatidylinositol 3-kinase/Akt-dependent mechanism.
  3. (2003). Cilostazol as a unique antithrombotic agent.
  4. (2010). Cilostazol enhances neovascularization in the mouse hippocampus after transient forebrain ischemia.
  5. (2005). Cilostazol in secondary prevention of stroke: impact of the Cilostazol Stroke Prevention Study.
  6. (2004). Cilostazol inhibits high glucose-mediated endothelial-neutrophil adhesion by decreasing adhesion molecule expression via NO production.
  7. (2001). Cilostazol represses vascular cell adhesion molecule-1 gene transcription via inhibiting NFkappaB binding to its recognition sequence.
  8. (1997). Cilostazol, a cAMP phosphodiesterase inhibitor, attenuates the production of monocyte chemoattractant protein-1 in response to tumor necrosis factor-alpha in vascular endothelial cells.
  9. (2001). Colombo A
  10. (2005). Coronary stent restenosis in patients treated with cilostazol.
  11. (2003). Crucial role of stromal cell-derived factor-1alpha in neointima formation after vascular injury in apolipoprotein E-deficient mice.
  12. (2010). CXCR4 gene transfer contributes to in vivo reendothelialization capacity of endothelial progenitor cells.
  13. (2007). CXCR4, a key modulator of vascular progenitor cells.
  14. (2004). Cytokine-induced mobilization of circulating endothelial progenitor cells enhances repair of injured arteries.
  15. (1985). Effect of cilostazol on platelet aggregation and experimental thrombosis.
  16. (1999). Effects of a single local administration of cilostazol on neointimal formation in ballooninjured rat carotid artery. Atherosclerosis 142: 41–46. Cilostazol Activates
  17. (2002). Endothelial progenitor cells for vascular regeneration.
  18. (2004). Endothelial progenitor cells: characterization, pathophysiology, and possible clinical relevance.
  19. (2007). Endothelial progenitor cells: sowing the seeds for vascular repair.
  20. (2003). Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells.
  21. (2003). Estrogen increases bone marrow-derived endothelial progenitor cell production and diminishes neointima formation.
  22. (2007). Expression of HIF-1alpha in injured arteries controls SDF-1alpha mediated neointima formation in apolipoprotein E deficient mice.
  23. (2009). From bone marrow to the arterial wall: the ongoing tale of endothelial progenitor cells.
  24. (2009). Hepatocyte growth factor, but not vascular endothelial growth factor, attenuates angiotensin II-induced endothelial progenitor cell senescence.
  25. (1985). High-performance liquid chromatographic procedure for the determination of a new antithrombotic and vasodilating agent, cilostazol, in human plasma.
  26. (2007). Highmobility group box 1 activates integrin-dependent homing of endothelial progenitor cells.
  27. (2001). HMGCoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway.
  28. (1999). Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty.
  29. (2010). Impaired endothelial repair capacity of early endothelial progenitor cells in prehypertension: relation to endothelial dysfunction.
  30. (2007). Importance of CXC chemokine receptor 2 in the homing of human peripheral blood endothelial progenitor cells to sites of arterial injury.
  31. (2006). Indication of long-term endothelial dysfunction after sirolimuseluting stent implantation.
  32. (2002). Inhibition of lipopolysaccharide-induced apoptosis by cilostazol in human umbilical vein endothelial cells.
  33. (2001). Inhibition of neointimal formation after balloon injury by cilostazol, accompanied by improvement of endothelial dysfunction and induction of hepatocyte growth factor in rat diabetes model.
  34. (1999). Ischemiaand cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization.
  35. (1997). Isolation of putative progenitor endothelial cells for angiogenesis.
  36. (2007). Matsumura A
  37. (2003). Mobilized endothelial progenitor cells by granulocyte-macrophage colony-stimulating factor accelerate reendothelialization and reduce vascular inflammation after intravascular radiation.
  38. (2005). Novel hepatocyte growth factor (HGF) binding domains on fibronectin and vitronectin coordinate a distinct and amplified Met-integrin induced signalling pathway in endothelial cells.
  39. (2007). Oxidant stress impairs in vivo reendothelialization capacity of endothelial progenitor cells from patients with type 2 diabetes mellitus: restoration by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone.
  40. (2002). Pharmacologic therapy for peripheral arterial disease and claudication.
  41. (2010). Phosphodiesterase III inhibition promotes differentiation and survival of oligodendrocyte progenitors and enhances regeneration of ischemic white matter lesions in the adult mammalian brain.
  42. (2004). Physical training increases endothelial progenitor cells, inhibits neointima formation, and enhances angiogenesis.
  43. (2005). Potent inhibitory effect of sirolimus on circulating vascular progenitor cells.
  44. (2006). Reduced 6-month resource use and costs associated with cilostazol in patients after successful coronary stent implantation: results from the Cilostazol for RESTenosis (CREST) trial.
  45. (2004). Remnant lipoprotein particles induce apoptosis in endothelial cells by NAD(P)H oxidase-mediated production of superoxide and cytokines via lectin-like oxidized low-density lipoprotein receptor-1 activation: prevention by cilostazol.
  46. (2005). Role of beta2-integrins for homing and neovascularization capacity of endothelial progenitor cells.
  47. (1997). Role of hepatocyte growth factor in endothelial regulation: prevention of high Dglucose-induced endothelial cell death by prostaglandins and phosphodiesterase type 3 inhibitor.
  48. (2010). SDF-1alpha involved in mobilization and recruitment of endothelial progenitor cells after arterial injury in mice.
  49. (2005). SDF-1alpha/CXCR4 axis is instrumental in neointimal hyperplasia and recruitment of smooth muscle progenitor cells.
  50. (2006). Sirolimus accelerates senescence of endothelial progenitor cells through telomerase inactivation.
  51. (2005). Soluble factors released by endothelial progenitor cells promote migration of endothelial cells and cardiac resident progenitor cells.
  52. (2002). Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells.
  53. (2005). Therapeutic potential of endothelial progenitor cells in cardiovascular diseases.
  54. (2004). Vascular repair by circulating endothelial progenitor cells: the missing link in atherosclerosis?
  55. (2008). Vascular repair by endothelial progenitor cells.
  56. (1999). VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells.
  57. (2002). Vitronectin is up-regulated after vascular injury and vitronectin blockade prevents neointima formation.